Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + TGA vs TGA in relapsed/refractory extracranial germ cell tumors in children and adolescents
ChiCTR2500110311Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thalidomide, paclitaxel, gemcitabine and epirubicin in germ cell tumor (GCT) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate (ORR). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
thalidomidepaclitaxelgemcitabineepirubicin
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ChiCTR2500110311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110311.